Research & Development Programme 2
OCT130401 is a drug/device combination, which will look like an asthma inhaler. Pre-clinical development for OCT130401 has been completed and it is ready to enter Phase I clinical trials. The initial target for OCT130401 is an orphan indication, Trigeminal Neuralgia.
Trigeminal Neuralgia
Trigeminal Neuralgia (TN) is a severe type of face pain. It causes debilitating and excruciating pain, has a fast and unexpected onset and because of this has been difficult to treat. People living with TN experience an intense, stabbing electric shock-like pain. Each episode may only last a few seconds or minutes, but some people will suffer multiple (up to 100) episodes in one day.[i] Our medicine will be designated orphan status and delivered via an inhaler which may mean faster onset of pain relief when compared to other routes.[ii]. Cases are increasing with between approximately 10,000 and 15,000 new cases in the United States diagnosed each year.[iii] We estimate that in 2021 there were more than 77,000 people living with the condition in the UK.[iv]
[i]https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Trigeminal-Neuralgia-Fact-Sheet
[ii] https://www.ncbi.nlm.nih.gov/books/NBK568677/
[iii] https://rarediseases.org/rare-diseases/trigeminal-neuralgia/
[iv] https://cks.nice.org.uk/topics/trigeminal-neuralgia/background-information/prevalence/